Search:
 
This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
-News
 NHF In The News
 NHF eNotes
 Medical Advisories
 Advocacy and Legislative Updates
 Medical News
 Blood Safety News
 NHF and Community News
-Industry News
 Travel Advisory

 

 

 
Achillion Drug Begins Phase 2 Trial in HCV Patients
 

In mid-April, Achillion Pharmaceuticals, Inc., initiated an international Phase 2 clinical trial evaluating its new drug ACH-3102, in combination with ribavirin and another one of its drugs, sovaprevir (ACH-1625), for the treatment of patients with chronic hepatitis C virus (HCV) infections, genotype 1.

 

ACH-3102 is a second-generation pan-genotypic (effective against all types of HCV) NS5A inhibitor. The NS5A protein directs production of virus particles, interacts with host proteins and is associated with interferon resistance. The 12-week trial will evaluate the effectiveness of the drug combination on previously untreated patients.

 

“In previous clinical trials, both sovaprevir and ACH-3102 were shown to be efficacious, safe, well-tolerated, and had demonstrated a high barrier to resistance. Hence, we believe that a combination of these two agents for the treatment of chronic hepatitis C has the potential to be well-tolerated and provide high SVR rates," commented Milind Deshpande, PhD, President of Research and Development and Chief Scientific Officer of Achillion.

 

Source: HartfordBusiness.com, April 16, 2013